Base de dados : MEDLINE
Pesquisa : C13.351.500.944 [Categoria DeCS]
Referências encontradas : 2797 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 280 ir para página                         

  1 / 2797 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29419702
[Au] Autor:Baradwan S; Wadi KA
[Ti] Título:Unilateral ectopic breast tissue on vulva in postpartum woman: A case report.
[So] Source:Medicine (Baltimore);97(6):e9887, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Ectopic mammary gland tissues occur in about 2% to 6% of women in general population. Vulva is considered a rare site for the ectopic breast tissue. PATIENT CONCERNS: We report a rare case of a 27 year-old woman, para 2 and presenting as a vulvar mass in the postpartum period. DIAGNOSES: Ectopic mammary tissue in vulva. INTERVENTIONS: The mass was removed by wide local excision. Histopathological assessment revealed features of ectopic mammary tissue CONCLUSION:: The vulvar region is one of the reported sites for ectopic breast tissue in the body. The presence of a rapidly enlarging, well-encapsulated mass in the vulvar region associated with recent delivery or lactation is suggestive of ectopic breast tissue. LESSONS: It is important for clinicians to get a good history and consider ectopic breast tissue on vulva in postpartum women and confirm diagnosis via biopsy with histopathological examination.
[Mh] Termos MeSH primário: Mama
Coristoma
Dissecação/métodos
Doenças da Vulva
[Mh] Termos MeSH secundário: Adulto
Biópsia/métodos
Coristoma/diagnóstico
Coristoma/patologia
Coristoma/cirurgia
Diagnóstico Diferencial
Feminino
Seres Humanos
Período Pós-Parto
Resultado do Tratamento
Doenças da Vulva/diagnóstico
Doenças da Vulva/patologia
Doenças da Vulva/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180209
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009887


  2 / 2797 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28470128
[Au] Autor:Parsons BF; Ryder N
[Ad] Endereço:1 Pacific Clinic Newcastle, HNE Sexual Health, Newcastle, NSW, Australia.
[Ti] Título:Pseudoepitheliomatous hyperplasia causing a painful plaque in a HIV-infected female.
[So] Source:Int J STD AIDS;28(7):723-725, 2017 06.
[Is] ISSN:1758-1052
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Dermatological conditions are more common and can present atypically, in human immunodeficiency virus-infected individuals. This case report describes a 22-year-old human immunodeficiency virus-positive Caucasian female who presented with a vulval lesion eight weeks after starting antiretroviral treatment. Clinical examination revealed a 2 cm well-demarcated plaque on the outer aspect of the left labium minus. The lesion was tender, no contact bleeding or ulceration present. She was presumptively treated for chancroid and herpes simplex with 500 mg ceftriaxone IM stat, 1 g azithromycin PO stat, and valacyclovir 500 mg BD for five days. The lesion persisted despite treatment, and during follow-up, a punch biopsy was carried out. She was diagnosed with pseudoepitheliomatous hyperplasia of the epidermis. In addition to highlighting this condition that has been previously reported in human immunodeficiency virus/herpes simplex virus co-infection, this case demonstrates that unusual skin presentations must be considered in human immunodeficiency virus-infected individuals and illustrates the importance of biopsy for any non-healing lesions.
[Mh] Termos MeSH primário: Infecções por HIV/complicações
Herpes Genital/diagnóstico
Hiperplasia/patologia
Vulva/patologia
Doenças da Vulva/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Fármacos Anti-HIV/uso terapêutico
Biópsia
Coinfecção/virologia
Feminino
Infecções por HIV/tratamento farmacológico
Herpes Genital/complicações
Herpes Genital/tratamento farmacológico
Herpes Genital/microbiologia
Seres Humanos
Hospedeiro Imunocomprometido
Simplexvirus
Resultado do Tratamento
Doenças da Vulva/complicações
Doenças da Vulva/tratamento farmacológico
Doenças da Vulva/microbiologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-HIV Agents)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:IM; X
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1177/0956462416676020


  3 / 2797 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29202940
[Au] Autor:Faubion SS; Sood R; Kapoor E
[Ad] Endereço:Women's Health Clinic, Division of General Internal Medicine, Mayo Clinic, Rochester, MN. Electronic address: faubion.stephanie@mayo.edu.
[Ti] Título:Genitourinary Syndrome of Menopause: Management Strategies for the Clinician.
[So] Source:Mayo Clin Proc;92(12):1842-1849, 2017 Dec.
[Is] ISSN:1942-5546
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Genitourinary syndrome of menopause (GSM), previously known as atrophic vaginitis or vulvovaginal atrophy, affects more than half of postmenopausal women. Caused by low estrogen levels after menopause, it results in bothersome symptoms, including vaginal dryness, itching, dyspareunia, urinary urgency and increased frequency, and urinary tract infections. Even though women with GSM can have sexual dysfunction that interferes with partner relationships, women are often embarrassed to seek treatment, and health care professionals do not always actively screen for GSM. As a result, GSM remains underdiagnosed and undertreated. Several effective treatments exist, but low-dose vaginal estrogen therapy is the criterion standard. It is effective and safe for most patients, but caution is suggested for survivors of hormone-sensitive cancers. Newer treatment options include selective estrogen receptor modulators, vaginal dehydroepiandrosterone, and laser therapy. Nonprescription treatments include vaginal lubricants, moisturizers, and dilators. Pelvic floor physical therapy may be indicated for some women with concomitant pelvic floor muscle dysfunction. Sex therapy may be helpful for women with sexual dysfunction. This concise review presents a practical approach to the evaluation and management of GSM for the primary care physician.
[Mh] Termos MeSH primário: Vaginite Atrófica/terapia
Menopausa
Incontinência Urinária/terapia
Doenças Vaginais/terapia
Doenças da Vulva/terapia
Saúde da Mulher
[Mh] Termos MeSH secundário: Terapia de Reposição de Estrogênios
Feminino
Seres Humanos
Meia-Idade
Qualidade de Vida
Síndrome
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171212
[Lr] Data última revisão:
171212
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE


  4 / 2797 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28711083
[Au] Autor:Micheletti RG; Dominguez AR; Wanat KA
[Ad] Endereço:Departments of Dermatology and Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: robert.micheletti@uphs.upenn.edu.
[Ti] Título:Bedside diagnostics in dermatology: Parasitic and noninfectious diseases.
[So] Source:J Am Acad Dermatol;77(2):221-230, 2017 Aug.
[Is] ISSN:1097-6787
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In addition to aiding the diagnosis of viral, bacterial, and fungal diseases, mineral oil preparation, Tzanck smear, and other techniques can be used to diagnose parasitic infections, neonatal pustular dermatoses, blistering diseases, Stevens-Johnson syndrome, and a plethora of other benign and malignant conditions, including granulomatous diseases and tumors. In many cases, these techniques are specific, reliable, and easy to perform and interpret. In others, a certain amount of training and expertise are required. In the proper clinical scenario, these tests are rapid, economical, and compare favorably with other diagnostic methods.
[Mh] Termos MeSH primário: Dermatologia/métodos
Testes Imediatos
Dermatopatias Parasitárias/diagnóstico
Dermatopatias Vesiculobolhosas/diagnóstico
Neoplasias Cutâneas/diagnóstico
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Leishmaniose Cutânea/diagnóstico
Infestações por Ácaros/diagnóstico
Oncocercose/diagnóstico
Neoplasias Cutâneas/patologia
Coloração e Rotulagem
Doenças Vaginais/diagnóstico
Doenças da Vulva/diagnóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170825
[Lr] Data última revisão:
170825
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170717
[St] Status:MEDLINE


  5 / 2797 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28697104
[Au] Autor:Wolters V; Hoogslag I; Wout JVT; Boers K
[Ad] Endereço:Departments of Gynecology and Obstetrics and Internal Medicine, Haaglanden Medical Center location Bronovo, The Hague, Academic Medical Center, Amsterdam, and the Department of Infectious Diseases and Immunology, Leiden University Medical Center, Leiden, the Netherlands.
[Ti] Título:Lipschütz Ulcers: A Rare Diagnosis in Women With Vulvar Ulceration.
[So] Source:Obstet Gynecol;130(2):420-422, 2017 Aug.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Lipschütz ulcers are characterized by painful vulvar ulceration, most commonly in young women. Because these lesions are so rarely seen, the diagnosis can be challenging. CASE: An 18-year-old woman, without any prior sexual activity, developed painful blue vulval lesions. These became necrotizing ulcers, and she began antiviral therapy for presumptive herpes infection. Herpes cultures, however, were negative. Serology consistent with a recent Epstein-Barr virus infection resulted in a diagnosis of Lipschütz ulcers. CONCLUSION: Lipschütz ulcers, associated with acute Epstein-Barr virus infection or other viral and bacterial infections, are a type of nonsexually transmitted vulvar ulceration. It is important to avoid selective attention to sexually transmitted infections as the etiology to avoid unnecessary antiviral therapy and immune suppressants. By considering other etiologies, the patient will be spared potentially embarrassing persistent questioning about her sexual history.
[Mh] Termos MeSH primário: Infecções por Vírus Epstein-Barr/diagnóstico
Úlcera/virologia
Doenças da Vulva/virologia
[Mh] Termos MeSH secundário: Adolescente
Analgésicos/uso terapêutico
Anticorpos Antivirais/sangue
Diagnóstico Diferencial
Feminino
Herpesvirus Humano 4/genética
Herpesvirus Humano 4/isolamento & purificação
Seres Humanos
Reação em Cadeia da Polimerase
Tonsilite/virologia
Úlcera/terapia
Doenças da Vulva/terapia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics); 0 (Antibodies, Viral)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170821
[Lr] Data última revisão:
170821
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170712
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0000000000002145


  6 / 2797 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28420227
[Au] Autor:Marrai R; Lissi G; Togni S; Maramaldi G; Barbara M; Giacomelli L
[Ad] Endereço:Obstetrics and Gynecology Unit, G. Pasquinucci Hospital, Massa, Italy.
[Ti] Título:Efficacy and tolerability of a plant-based, multi-component cream (Ginetrox®) in vulvovaginal disorders of the genitourinary syndrome during menopause.
[So] Source:Minerva Ginecol;69(3):245-249, 2017 Jun.
[Is] ISSN:1827-1650
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Genitourinary syndrome of menopause (GSM) is a symptomatic condition including vaginal dryness, irritation, dyspareunia and recurrent urinary tract infections which affects 40-54% of post-menopausal women. Although several estrogen-based therapies are available, it is generally preferable to avoid hormonal therapy, particularly in women with mild symptoms or at risk for estrogen-responsive neoplasia. Therefore, the most common treatment options are over-the-counter vaginal creams for symptomatic relief. METHODS: Thirty-three postmenopausal women suffering from GSM were enrolled in this observational study. A multi-component cream (Ginetrox®, Indena, Milan, Italy) was applied on the vestibular area of the vagina for three months. The primary endpoints were: vaginal burning and/or pain, assessed by Visual Analog Scale and dyspareunia, assessed using the Marinoff Score. As a secondary endpoint, vestibular health was evaluated through a four-point scale. Side effects and adherence to treatment were also recorded. RESULTS: Statistically significant improvement was observed in pain scores and dyspareunia at the end of the treatment compared to baseline values. The vestibular health index significantly decreased after 3 months. Tolerability was acceptable. CONCLUSIONS: This preliminary study suggests that the plant-based, multi-component cream Ginetrox® could be effective and safe in counteracting menopause-related vaginal discomfort symptoms.
[Mh] Termos MeSH primário: Menopausa
Preparações de Plantas/administração & dosagem
Doenças Vaginais/tratamento farmacológico
Doenças da Vulva/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Intravaginal
Idoso
Dispareunia/tratamento farmacológico
Dispareunia/etiologia
Feminino
Seres Humanos
Itália
Adesão à Medicação
Meia-Idade
Dor/epidemiologia
Dor/etiologia
Preparações de Plantas/efeitos adversos
Síndrome
Resultado do Tratamento
Cremes, Espumas e Géis Vaginais
Doenças Vaginais/etiologia
Doenças da Vulva/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Plant Preparations); 0 (Vaginal Creams, Foams, and Jellies)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170420
[St] Status:MEDLINE
[do] DOI:10.23736/S0026-4784.17.04015-1


  7 / 2797 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28381294
[Au] Autor:Cocchio S; Baldovin T; Bertoncello C; Buja A; Furlan P; Saia M; Baldo V
[Ad] Endereço:Institute of Hygiene, Laboratory of Public Health and Population Studies, University of Padua, Via Loredan 18, 35121, Padua, Italy.
[Ti] Título:Decline in hospitalization for genital warts in the Veneto region after an HPV vaccination program: an observational study.
[So] Source:BMC Infect Dis;17(1):249, 2017 Apr 05.
[Is] ISSN:1471-2334
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Human papillomavirus (HPV) is one of the most common sexually transmitted pathogens. This observational study was conducted to estimate the trend of hospitalization for genital warts (GWs) in the Veneto region (Italy) from 2004 to 2015. METHODS: All patients with GWs were identified in the hospital discharge records of all public and accredited private hospitals that related to Veneto residents and contained the ICD9-CM code 078.11 associated with a genital surgical procedure (vulval/vaginal warts, penile warts and anal warts). Annual total and sex- and age-specific hospitalization rates and trends were calculated and correlated with the different HPV vaccine coverage over the study period. RESULTS: An annual rate of 11.8 per 100,000 population (8.6 per 100,000 males, and 14.8 per 100,000 females) was found, corresponding to 6076 hospitalizations for condyloma (53.3% vulval/vaginal, 35.8% anal, 8.3% penile, and 2.6% both penile or vulval/vaginal and anal). Among females, the rate of overall GWs remained stable to 2007 (19.1 per 100,000), then dropped significantly, reaching a rate of 11.3 per 100,000 in 2015 (average annual percent changes [AAPC]: -6.1%; 95% CI: -8.4; -3.7). For males, the overall rate increased over the study period (from 6.4 per 100,000 in 2004 to 10.8 per 100,000 in 2015; AAPC: 3.8%; 95% CI: 1.2; 6.4). Among the potentially vaccinated females (12- to 20-year-olds) there was a 62.1% decrease in the number of vulval/vaginal warts from the years 2010-2012 to the years 2013-2015 due to an increase in the HPV coverage rate. A similar reduction among males was observed in the same period and the same age group for penile warts (-68.2%). CONCLUSION: GWs have an important impact on the health services and data suggest that GW-related hospitalization rates rapidly decline in a population with a high HPV vaccination coverage (about 75%). Further efforts should be made to better clarify the epidemiological picture regarding HPV-related diseases, with particular regard to sexual behavior.
[Mh] Termos MeSH primário: Condiloma Acuminado/prevenção & controle
Hospitalização/estatística & dados numéricos
Vacinas contra Papillomavirus/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Condiloma Acuminado/epidemiologia
Feminino
Seres Humanos
Itália
Masculino
Papillomaviridae/imunologia
Vacinas contra Papillomavirus/imunologia
Doenças do Pênis/prevenção & controle
Doenças do Pênis/virologia
Comportamento Sexual
Doenças da Vulva/prevenção & controle
Doenças da Vulva/virologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Papillomavirus Vaccines)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170628
[Lr] Data última revisão:
170628
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170407
[St] Status:MEDLINE
[do] DOI:10.1186/s12879-017-2361-5


  8 / 2797 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28364869
[Au] Autor:Simon JA; Archer DF; Constantine GD; Pickar JH; Amadio JM; Bernick B; Graham S; Mirkin S
[Ad] Endereço:The George Washington University School of Medicine, Washington, DC, United States.
[Ti] Título:A vaginal estradiol softgel capsule, TX-004HR, has negligible to very low systemic absorption of estradiol: Efficacy and pharmacokinetic data review.
[So] Source:Maturitas;99:51-58, 2017 May.
[Is] ISSN:1873-4111
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:This paper reviews the efficacy, safety, and systemic absorption of estradiol with TX-004HR, an investigational, low-dose 17ß-estradiol vaginal softgel capsule, designed to treat vulvar and vaginal atrophy (VVA) in postmenopausal women, with an improved user experience. In phase 2 (NCT02449902) and phase 3 REJOICE (NCT02253173) studies, TX-004HR significantly improved the proportions of vaginal superficial and parabasal cells and vaginal pH, and in the phase 3 study decreased the severity of dyspareunia, vaginal dryness, and vulvar and/or vaginal itching or irritation. In two randomized, phase 1 trials, estradiol C and AUC were significantly lower with 10µg and 25µg TX-004HR than with the same doses of an approved vaginal estradiol tablet. A substudy (n=72) of the REJOICE trial showed that estradiol C and AUC with 4µg and 10µg TX-004HR were not different from placebo on days 1 and 14. While TX-004HR 25µg was associated with higher C and AUC versus placebo on days 1 and 14, these levels remained within the postmenopausal range. Estradiol day-84 values for all three doses were not different from placebo, demonstrating no estradiol accumulation. All TX-004HR doses were well tolerated and had an acceptable safety profile in all reviewed studies. The local vaginal efficacy of TX-004HR was significantly better than that of placebo, while the overall safety profile was similar to that of placebo. Negligible to very low systemic estradiol absorption was observed whether given at 4, 10, or 25µg. If approved, TX-004HR may be an alternative option for women with symptomatic VVA without increasing mean systemic estradiol absorption above postmenopausal levels.
[Mh] Termos MeSH primário: Estradiol/administração & dosagem
Estrogênios/administração & dosagem
Doenças Vaginais/tratamento farmacológico
Doenças da Vulva/tratamento farmacológico
[Mh] Termos MeSH secundário: Absorção Fisiológica
Administração Intravaginal
Atrofia
Cápsulas
Método Duplo-Cego
Dispareunia/tratamento farmacológico
Estradiol/farmacocinética
Estradiol/uso terapêutico
Terapia de Reposição de Estrogênios/métodos
Estrogênios/farmacocinética
Feminino
Seres Humanos
Pós-Menopausa
Vagina/patologia
Vulva/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Capsules); 0 (Estrogens); 4TI98Z838E (Estradiol)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170602
[Lr] Data última revisão:
170602
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170403
[St] Status:MEDLINE


  9 / 2797 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28364861
[Au] Autor:Gambacciani M; Palacios S
[Ad] Endereço:Department of Obstetrics and Gynaecology, Pisa University Hospital, Pisa, Italy. Electronic address: margamba54@gmail.com.
[Ti] Título:Laser therapy for the restoration of vaginal function.
[So] Source:Maturitas;99:10-15, 2017 May.
[Is] ISSN:1873-4111
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:Laser therapy has a therapeutic role in various medical conditions and most recently has gained interest as a non-hormonal treatment for genitourinary syndrome of menopause (GSM) and as a non-invasive option for stress urinary incontinence (SUI). Several therapies are available to alleviate GSM symptoms, including hormonal and non-hormonal products. Both microablative fractional CO laser and the non-ablative vaginal Er:YAG laser (VEL) induce morphological changes in the vaginal tissues, and data from non-randomized clinical trials suggest that laser therapy can alleviate vaginal dryness and dyspareunia. VEL has been reported to improve SUI as well as vaginal prolapse. Although large randomized trials have not been reported, the evidence suggests that VEL can be offered as a safe and efficacious alternative to hormone replacement therapy (HRT) for GSM, as well as a first-line treatment for mild to moderate SUI, before surgical procedures are resorted to. Randomized studies are needed to compare laser treatments with other therapies, as well as to assess the duration of the therapeutic effects and the safety of repeated applications. Research is presently evaluating both an automated robotic probe for VEL treatments and an intraurethral probe for the treatment of severe and type III SUI.
[Mh] Termos MeSH primário: Terapia a Laser/métodos
Lasers de Gás/uso terapêutico
Lasers de Estado Sólido/uso terapêutico
Terapia com Luz de Baixa Intensidade/métodos
Menopausa
Incontinência Urinária por Estresse/terapia
Prolapso Uterino/terapia
Doenças Vaginais/terapia
Doenças da Vulva/terapia
[Mh] Termos MeSH secundário: Atrofia
Dispareunia/terapia
Feminino
Seres Humanos
Síndrome
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170602
[Lr] Data última revisão:
170602
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170403
[St] Status:MEDLINE


  10 / 2797 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28259230
[Au] Autor:Marnach ML; Torgerson RR
[Ad] Endereço:Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN. Electronic address: marnach.mary@mayo.edu.
[Ti] Título:Vulvovaginal Issues in Mature Women.
[So] Source:Mayo Clin Proc;92(3):449-454, 2017 Mar.
[Is] ISSN:1942-5546
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Mature women often present with symptomatic vulvovaginal atrophy and vulvar dermatoses, causing noncoital pain, dyspareunia, and sexual changes. Diagnosis of these conditions can be challenging, and long-term management is required to decrease morbidity and enhance quality of life. Vaginal estrogen therapies remain safe and effective for treating symptomatic vulvovaginal atrophy. A vulvar biopsy is easy to perform and generally well tolerated when indicated for the diagnosis of lichen simplex chronicus, lichen sclerosus, and lichen planus. Therapy with moderate- to high-potency corticosteroids is effective for these frequently debilitating conditions.
[Mh] Termos MeSH primário: Dispareunia/etiologia
Estrogênios/administração & dosagem
Pós-Menopausa/fisiologia
Disfunções Sexuais Fisiológicas/diagnóstico
Dermatopatias/diagnóstico
Vulva/patologia
Doenças da Vulva/diagnóstico
Saúde da Mulher
[Mh] Termos MeSH secundário: Administração Intravaginal
Atrofia/tratamento farmacológico
Fármacos Dermatológicos/administração & dosagem
Fármacos Dermatológicos/uso terapêutico
Diagnóstico Diferencial
Dispareunia/prevenção & controle
Terapia de Reposição de Estrogênios/métodos
Estrogênios/uso terapêutico
Feminino
Seres Humanos
Líquen Plano/diagnóstico
Líquen Plano/tratamento farmacológico
Neurodermatite/diagnóstico
Neurodermatite/tratamento farmacológico
Qualidade de Vida
Disfunções Sexuais Fisiológicas/tratamento farmacológico
Disfunções Sexuais Fisiológicas/etiologia
Dermatopatias/tratamento farmacológico
Cremes, Espumas e Géis Vaginais/administração & dosagem
Cremes, Espumas e Géis Vaginais/uso terapêutico
Doenças da Vulva/tratamento farmacológico
Líquen Escleroso Vulvar/diagnóstico
Líquen Escleroso Vulvar/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Dermatologic Agents); 0 (Estrogens); 0 (Vaginal Creams, Foams, and Jellies)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170609
[Lr] Data última revisão:
170609
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170306
[St] Status:MEDLINE



página 1 de 280 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde